Laroscorbine (Ascorbic Acid)

Ascorbic acid serves as a cofactor for enzymes involved in collagen synthesis, neurotransmitter production, and hormone metabolism. It also acts as a potent antioxidant, neutralizing free radicals, regenerating other antioxidants, and supporting immune cell function, which together help maintain tissue integrity and host defenses.

The appropriate dose of Laroscorbine is determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function, and therapeutic goals. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for intravenous ascorbic acid in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible. Pregnant or nursing patients should only use Laroscorbine if clearly indicated by a healthcare professional.

To order Laroscorbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Laroscorbine is a pharmaceutical‑grade intravenous ascorbic acid, offering higher purity and controlled sterility compared with oral supplements. Intravenous delivery achieves much higher plasma concentrations rapidly, which can be advantageous in acute deficiency or when oral absorption is compromised, whereas oral products provide lower, more gradual increases.

Laroscorbine should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the product. Before use, inspect for particulate matter or discoloration and follow aseptic techniques for preparation and administration.

Laroscorbine is administered intravenously by a qualified healthcare professional. The solution is typically infused over a prescribed period, often using an infusion pump or controlled drip, to ensure safe delivery and to monitor for any infusion‑related reactions.

Serious risks include oxalate nephropathy leading to renal impairment, hemolysis in patients with G6PD deficiency, severe allergic reactions such as anaphylaxis, and profound hypotension during infusion. Patients should be monitored closely for these events, especially those with pre‑existing kidney disease or enzyme deficiencies.

Laroscorbine should be avoided in individuals with known G6PD deficiency, severe renal impairment, or a history of hypersensitivity to ascorbic acid or any component of the formulation. It is also contraindicated in patients receiving medications that may precipitate oxalate formation without appropriate monitoring.